Keck School of Medicine of USC

Larta Institute Opens Call for Applications to Heal.LA Bioscience and Healthcare Accelerator

Retrieved on: 
Wednesday, November 8, 2023
Other Health, General Health, Professional Services, Entrepreneur, Philanthropy, Consumer, Start-Up, Small Business, Science, Biotechnology, Other Philanthropy, Health, Other Science, Knowledge, Rancho Los Amigos National Rehabilitation Center, Health care, Therapy, Food, Healing environments, Mental health, USC, Heal, California State University, Organization, Holism, Entrepreneurship, Gilead Sciences, Small business, Consortium, Medicine, Cedars-Sinai Medical Center, Keck Graduate Institute, Rio Hondo College, Innovation Hub, Keck School of Medicine of USC, SBA, California Office of Environmental Health Hazard Assessment, WuXi Biologics, Hospital, Management, New England Biolabs, Pediatrics

Larta Institute, a non-profit organization accelerating innovation and entrepreneurship to feed, fuel and heal the world, has opened a call for applicants to join the 2024 cohort of its Heal.LA Bioscience and Healthcare Accelerator.

Key Points: 
  • Larta Institute, a non-profit organization accelerating innovation and entrepreneurship to feed, fuel and heal the world, has opened a call for applicants to join the 2024 cohort of its Heal.LA Bioscience and Healthcare Accelerator.
  • The Heal.LA accelerator welcomes applications from innovators with ideas that have the potential to improve the health and wellness of underserved, urban communities.
  • Larta has designed our Heal.LA Bioscience and Healthcare Accelerator to help diverse founders advance innovations geared to the needs of underserved communities and to pilot the use of their solutions in these communities.
  • To learn more or apply to the Heal.LA Bioscience and Healthcare Accelerator, please visit: https://larta.org/programs/heal-accelerator/

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

Retrieved on: 
Tuesday, October 31, 2023
Therapy, Keck School of Medicine of USC, Assistant, AMD, Consultant, Partnership, KOL, Medicine, University, Baystate Health, Massachusetts Medical Society, University of Southern California, Patient, Retina, New England, Pharmaceutical industry, Hospital, Ophthalmology

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET.

Key Points: 
  • WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET.
  • This event will focus on the potential of EYP-1901 in wet age-related macular degeneration (wet AMD), including KOL perspectives on the current wet AMD treatment landscape, vorolanib’s unique mechanism of action and outcome considerations for the upcoming topline data read-out for the DAVIO 2 trial in December.
  • A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com .
  • A webcast replay will also be available on the corporate website at the conclusion of the call.

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PureTech Health, Keck School of Medicine of USC, Incidence, Central nervous system, Aes, IPF, University, Survival, University of Southern California, Vital capacity, FDA, Idiopathic pulmonary fibrosis, PRTC, LSE, TID, CNS, Patient, Poster, Pharmaceutical industry, Medicine

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, presented clinical data supporting the differentiated profile of LYT-100 (deupirfenidone) at the CHEST Annual Meeting in Honolulu, Hawaii.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, presented clinical data supporting the differentiated profile of LYT-100 (deupirfenidone) at the CHEST Annual Meeting in Honolulu, Hawaii.
  • The presentation expands on data from a completed trial of LYT-100 in healthy older adults, which informed the two doses selected for the ongoing, global Phase 2b dose-ranging trial of LYT-100 (ELEVATE IPF) in patients with idiopathic pulmonary fibrosis (IPF).
  • The trial showed that a 550 mg dose of LYT-100 given three times daily (TID) provided bioequivalent drug exposure to the FDA-approved dose of pirfenidone, 801 mg TID.
  • LYT-100 also demonstrated a 24% lower peak drug concentration than pirfenidone, which is a key factor generally associated with tolerability.

Clarius L20 HD3 Receives Highest Image Quality Ranking Among Five Point-of-Care Ultrasound Devices

Retrieved on: 
Tuesday, September 26, 2023
University, Face, Teaching, Intelligence, Android, SAGE Publishing, Artery, Associate, IOS, POCUS, Medicine, L15, MD, Patient, L20, Ophthalmology, Clarius, Keck School of Medicine of USC, Growth, Skin, Wireless, Medical imaging, Medical device

VANCOUVER, BC , Sept. 26, 2023 /PRNewswire/ -- Clarius Mobile Health, a global leader in wireless ultrasound solutions, is pleased to announce that the Clarius L20 HD3 and Clarius L15 HD3 received first and second place rankings in an independent research study conducted at the Keck School of Medicine of University of Southern California by Kristen E Park, Preeya Mehta, Charlene Tran, Alomi O Parikh, Qifa Zhou, and Sandy Zhang-Nunes.

Key Points: 
  • The Clarius L20 HD3 received the highest mean rating, followed by the Clarius L15 HD3.
  • "The L20 received the highest image quality rankings," the study notes, "followed by the L15 … (p
  • Wireless and priced at a small fraction of the cost of traditional ultrasound systems, Clarius scanners operate with an easy-to-use app on iOS and Android devices.
  • Ultrasound.

Los Angeles Cancer Network Opens New Location in Santa Clarita

Retrieved on: 
Tuesday, September 19, 2023
Olive, Cedars-Sinai Medical Center, University, Internal medicine, Patient, Central European, Cancer, Olive View–UCLA Medical Center, Physician, Semmelweis University, Keck School of Medicine of USC, Harbor–UCLA Medical Center, University of Mississippi Medical Center, Nursing

SANTA CLARITA, Calif., Sept. 19, 2023 /PRNewswire/ -- Los Angeles Cancer Network (LACN) has been a trusted provider of cancer and blood disorder care in the Los Angeles area for over 30 years.

Key Points: 
  • SANTA CLARITA, Calif., Sept. 19, 2023 /PRNewswire/ -- Los Angeles Cancer Network (LACN) has been a trusted provider of cancer and blood disorder care in the Los Angeles area for over 30 years.
  • Last week, on September 12, 2023, the ribbon was cut at their newest location at 25425 Orchard Village Rd.
  • Suite 150, Santa Clarita, CA 91355, where they will be providing world-class care to patients in the Santa Clarita and surrounding communities.
  • Board-certified hematologist/oncologists Dr. Sheila Vasan and Dr. Krisztina Larson will practice at the newest location in Santa Clarita.

Dr. Richard Merkin Honors the 2023 Graduating Class at the Heritage Institute of Clinical Studies at USC

Retrieved on: 
Friday, September 15, 2023
Online, HPN, Partnership, University, Education, Diabetes, Public health, Heart, Atrial fibrillation, Spanish Cultural Heritage Institute, Bipolar disorder, Keck School of Medicine of USC, Medicine, HICS, USC, Certification, Hypertension, DO, Student, MD, RN, Health, MPH, Clinical, Alzheimer's disease, Nursing, Doctor of Philosophy, LVN

NORTHRIDGE, Calif., Sept. 15, 2023 /PRNewswire/ -- Dr. Richard Merkin, Founder and CEO of Heritage Provider Network, (HPN) one of the country's largest physician founded and physician owned integrated healthcare systems, honored 46 graduating HPN employees enrolled in the Heritage Institute of Clinical Studies, a partnership program at the University of Southern California.  https://www.youtube.com/watch?v=2qEUjZfb3xg

Key Points: 
  • "The only difference between ordinary and extraordinary is that little extra, and that little extra is represented by all of you here today.
  • I want to celebrate you, thank you and very much congratulate you for what you've accomplished, thank you very much," said Dr. Merkin.
  • We came, we studied, we conquered," said Heno Yousefi, 2023 HICS graduate, clinical pharmacist, HPN.
  • After the ceremony, graduates and guests were honored at a dinner reception in Town and Gown celebrating their achievements that emphasize the Heritage Institute of Clinical studies goal-Virtus Orci-clinical power.

PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer

Retrieved on: 
Tuesday, September 12, 2023
Office of Criminal Investigations, Medicine, BPH, Quality of life, Research, USC, NYU Langone Health, Patient, Investigational device exemption, Keck School of Medicine of USC, IDE, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Prostate cancer, Pharmaceutical industry, Aquablation therapy, Urology

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today the Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to investigate the safety and efficacy of Aquablation therapy for prostate cancer.

Key Points: 
  • REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today the Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to investigate the safety and efficacy of Aquablation therapy for prostate cancer.
  • The study will enroll patients with localized prostate cancer at three prestigious cancer centers, Keck Medical Center of USC, Perlmutter Cancer Center at NYU Langone Health, and Mount Sinai Tisch Cancer Center.
  • “Aquablation Therapy, recognized for its efficacy and safety in resecting prostate tissue for BPH, offers a potential paradigm shift in how urologists might address localized prostate cancer.
  • Reza Zadno, CEO of PROCEPT BioRobotics, remarked, "Receiving IDE approval to explore Aquablation Therapy for men with localized prostate cancer marks a pivotal moment for PROCEPT.

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

Retrieved on: 
Wednesday, September 6, 2023
Medical genetics, FRCP, University, Royal Free Hospital, University of the Witwatersrand, BioMarin Pharmaceutical, Consultant, Keck School of Medicine of USC, Achondroplasia, Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of Southern California, BMRN, Division, University of Minnesota Medical School, SAN, NHS foundation trust, Evelina London Children's Hospital, Hospital, Haemophilia, Master of Medicine, Hemostasis, Broadcasting, Instrumentation, Pediatrics, Bachelor of Medicine, Bachelor of Surgery, Endocrinology

SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.

Key Points: 
  • R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th
    SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m.
  • ET on Tuesday, September 12, 2023.
  • BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.
  • An archived version of the remarks will also be available through the Company's website for a limited time following the event.

The Scleroderma Research Foundation (SRF) Launches Conquest Trial Platform to Address Critical Issues in Clinical Development and Enable Advances in Scleroderma Therapeutics

Retrieved on: 
Tuesday, August 1, 2023
General Health, Foundation, Health, Philanthropy, Scleroderma Research Foundation, Drug development, University, Therapy, Atmosphere, Clinical trial, Cancer, British Lung Foundation, ILD, Keck School of Medicine of USC, Research, FVC, CONQUEST, Autoimmunity, Fibrosis, Vital capacity, SRF, Imperial College London, MD, Patient, Autoimmune disease, Vascular disease, Rheumatology, Disease, Frederick, Knowledge, Ecosystem, Respiratory Medicine, British, Pharmaceutical industry, Vaccine, Medicine, Scleroderma, Sanofi

This groundbreaking effort, conceived and led by the SRF, will enroll patients across more than 130 centers in more than 22 countries. CONQUEST offers advantages to all stakeholders -- patients, physician, and drug innovators -- and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF and its pharmaceutical partners expect to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.

Key Points: 
  • The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Sanofi will contribute the first experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
  • In the future, the CONQUEST platform will be expanded to address other manifestations of scleroderma.
  • Luke Evnin, Ph.D., Chairman of the Scleroderma Research Foundation, commented, “Our commitment to innovation in scleroderma spans basic, translational, and clinical research.
  • The initial run of CONQUEST is expected to enroll approximately 400 patients and trial initiation is targeted for Q4 2023.

Hyundai and Children's Hospital Los Angeles Host Child Safety Seat Check and Pedestrian Safety Event

Retrieved on: 
Tuesday, July 18, 2023
Social responsibility, Children's Hospital Los Angeles, Partnership, Injury, Progress in Human Geography, Hyundai Motor Manufacturing Alabama, Medicine, Hospital, CHLA, Hyundai Motor America, Keck School of Medicine of USC, Molina Healthcare, Physician, Hyundai Motor Company, Multimedia, Blog, Children's Hospital, USC, National Institutes of Health, Bangladesh Technical Education Board, Progress, Organization, Walking, Pediatrics, Child, SUV, Humanity, Knowledge, Health, Death, News, Safety, Automotive industry, Nursing, Hyundai

FOUNTAIN VALLEY, Calif., July 18, 2023 /PRNewswire/ -- Hyundai Motor America hosted a child safety seat check and pedestrian safety event at its national headquarters in Fountain Valley, California with Children's Hospital Los Angeles (CHLA) .

Key Points: 
  • FOUNTAIN VALLEY, Calif., July 18, 2023 /PRNewswire/ -- Hyundai Motor America hosted a child safety seat check and pedestrian safety event at its national headquarters in Fountain Valley, California with Children's Hospital Los Angeles (CHLA) .
  • "We are proud to continue growing our partnership with CHLA by expanding the child safety seat and pedestrian safety programming to Orange County—at our very own Hyundai Motor America regional headquarters," said Brian Latouf, global chief safety officer, Hyundai Motor Company.
  • The two-part event featured both a child safety seat check and a pedestrian safety training at the Hyundai national headquarters.
  • Founded in 1901, Children's Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No.